Z-Butylidenephthalide

Z-Butylidenephthalide

SCHEMBL290482

CCC/C=C1\OC(=O)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 1.00
ALDH1A1 P00352 4/20 0.73
TSHR P16473 1/20 0.73
MAPK1 P28482 1/20 0.73
KDM4E B2RXH2 4/20 0.50
HPGD P15428 3/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
TDP1 Q9NUW8 2/20 0.50
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
NFKB1 P19838 1/20 0.49
NFKB2 Q00653 1/20 0.49
RELA Q04206 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
ALOX15 P16050 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Z-Butylidenephthalide SCHEMBL30268972 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL290483 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL27581583 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL29372485 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
(E)-Butylidenephthalide SCHEMBL783051 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL28057404 1.00 TRPA1 (1.00) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL27312198 0.98 TRPA1 (0.96) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL28057401 0.92 TRPA1 (0.84) TRPA1ALDH1A1TSHRMAPK1KDM4E
SCHEMBL6530791 0.89 TRPA1 (0.81) TRPA1ALDH1A1TSHRMAPK1KDM4E
Z-Butylidenephthalide SCHEMBL28165145 0.89 TRPA1 (0.79) TRPA1ALDH1A1TSHRMAPK1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 314 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250295123-A1 Arthropod Control Compositions FIRMENICH & CIE (CH) 2025-09-25 US claimed
US-20230247992-A1 ARTHROPOD CONTROL COMPOSITION FIRMENICH & CIE (CH) 2023-08-10 US claimed
WO-2023117960-A1 ARTHROPOD CONTROL COMPOSITIONS FIRMENICH SA (CH) 2023-06-29 WO claimed
EP-4181681-A1 ARTHROPOD CONTROL COMPOSITION Firmenich SA (CH) 2023-05-24 EP claimed
CN-115867139-A Arthropod control composition 弗门尼舍有限公司 2023-03-28 CN claimed
CN-114989891-A Angelica essential oil and preparation method and application thereof 湖南诺泽生物科技有限公司 2022-09-02 CN claimed
WO-2022013204-A1 ARTHROPOD CONTROL COMPOSITION FIRMENICH SA (CH) 2022-01-20 WO claimed
CN-109069478-B Application of Z-butylidene phthalide in activating autoimmune system 长弘生物科技股份有限公司 2021-07-06 CN claimed
EP-3208267-B1 METHOD FOR PREPARING ISOBENZOFURAN-1(3H)-ONE COMPOUND EVERFRONT BIOTECH INC (TW) 2020-12-23 EP claimed
EP-3466422-B1 USE OF Z-BUTYLIDENEPHTHALIDE IN ACTIVATING AUTOIMMUNE SYSTEM EVERFRONT BIOTECH INC (TW) 2020-11-18 EP claimed
CN-102579434-B pharmaceutical composition for treating brain cancer or for reducing resistance of brain cancer cells to temozolomide UNIV CHINA MEDICAL 2014-03-19 CN claimed
EP-2621462-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR The Procter and Gamble Company (US) 2013-08-07 EP claimed
EP-2438914-B1 Pharmaceutical composition comprising Z-butylidenephthalide for treating brain cancer or reducing temozolomide-resistance of brain cancer cells UNIV CHINA MEDICAL (TW) 2013-05-08 EP claimed
CN-102579434-A Pharmaceutical composition for treating brain cancer or for reducing resistance of brain cancer cells to temozolomide UNIV CHINA MEDICAL 2012-07-18 CN claimed
US-20120178803-A1 METHOD FOR TREATING BRAIN CANCER OR REDUCING TEMOZOLOMIDE-RESISTANCE OF BRAIN CANCER CELLS CHINA MEDICAL UNIVERSITY (TW) 2012-07-12 US claimed
WO-2012044728-A1 ORAL CARE COMPOSITIONS WITH IMPROVED FLAVOR THE PROCTER & GAMBLE COMPANY (US) 2012-04-05 WO claimed
US-20120082628-A1 Oral Care Compositions With Improved Flavor THE PROCTER & GAMBLE COMPANY 2012-04-05 US claimed
EP-2343051-A2 Anti-cancer formulation National Dong Hwa University (TW) 2011-07-13 EP claimed
US-20110165201-A1 ANTICANCER FORMULATION NATIONAL DONG HWA UNIVERSITY (TW) 2011-07-07 US claimed
CN-1041725-C Method for synthetising 3-butenyl phthalide UNIV LANZHOU (CN) 1999-01-20 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178803-A1 METHOD FOR TREATING BRAIN CANCER OR REDUCING TEMOZOLOMIDE-RESISTANCE OF BRAIN CANCER CELLS MGMT, SLC11A2, GABARAPL2 TRPA1 4405/4885ALDH1A1 1034/4885TSHR 2943/4885
US-20120082628-A1 Oral Care Compositions With Improved Flavor TRPA1, TAS2R40, TAS2R30 TRPA1 1/4885ALDH1A1 1558/4885TSHR 1962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.